RESUMO
This prospective randomized study incorporates 141 surgical department patients with hepatobiliary tumors. The 1st group patients received 800 ml/day of remaxol. The 2nd1 group patients received Ringer solution and 10% glucose at 1:1 ratio. The subgroups included: 1 subgroup-with pre-operative cholecysto- or choledochostomia and B-subgroup-without pre-operative interventions. The combined surgical and pharmaceutical correction of bile passage, bilirubinemia, cholestasis and cytolysis by remaxole leads to better hepatic dysfunction correction and allows better timing of chemotherapy in bile passage tumors.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias dos Ductos Biliares/tratamento farmacológico , Neoplasias dos Ductos Biliares/cirurgia , Ductos Biliares Intra-Hepáticos/cirurgia , Colecistostomia , Coledocostomia , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/cirurgia , Fígado/fisiopatologia , Succinatos/uso terapêutico , Adulto , Idoso , Neoplasias dos Ductos Biliares/fisiopatologia , Ductos Biliares Intra-Hepáticos/efeitos dos fármacos , Ductos Biliares Intra-Hepáticos/fisiopatologia , Quimioterapia Adjuvante , Colestase/tratamento farmacológico , Colestase/cirurgia , Feminino , Humanos , Hiperbilirrubinemia/tratamento farmacológico , Hiperbilirrubinemia/cirurgia , Fígado/efeitos dos fármacos , Fígado/metabolismo , Testes de Função Hepática , Neoplasias Hepáticas/fisiopatologia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Substâncias Protetoras/uso terapêuticoRESUMO
The investigations were performed in 139 patients divided into 3 groups and who were given similar volume of infusion therapy (1600 ml/day). In the first group consisting of 54 patients the solution of infusion therapy included the Ringer solution and 10% of glucose solution in the ratio 1:1. In the second group (37 patients) the infusion therapy was performed with a solution of sterofundin-G-5. In the third group (48 patients) remaksol in dose 800 ml/day was included in infusion therapy. The inclusion of sterofundin-G-5 and remaksol in the infusion therapy increased the rate of bile outflow at the early postoperative period as compared with the solutions of Ringer and 10% of glucose. Remaksol is better for arresting endotoxicosis and bile excreting function of the liver as compared with infusion of sterofundin-G-5.
Assuntos
Bile/efeitos dos fármacos , Glucose/administração & dosagem , Soluções Isotônicas/administração & dosagem , Icterícia Obstrutiva/terapia , Cuidados Pré-Operatórios/métodos , Succinatos/administração & dosagem , Bile/metabolismo , Bilirrubina/sangue , Combinação de Medicamentos , Feminino , Humanos , Infusões Intravenosas , Icterícia Obstrutiva/metabolismo , Icterícia Obstrutiva/fisiopatologia , Fígado/metabolismo , Fígado/fisiopatologia , Masculino , Compostos Orgânicos/administração & dosagem , Solução de Ringer , Resultado do TratamentoRESUMO
The influence of the infusion therapy content on a hepatic function of bile outflow (HFBO), a bilirubin content and the enzymes activity in obturation jaundice in 139 patients was studied up. In 54 patients (the first group) a Ringer solution and 10% solution of glucose in 1:1 ratio were applied; in 37 patients (the second group) - a sterofundin-G-5 solution; in 48 patients (the third group) - remaxol in a dose of 800 ml/day. Application of sterofundin-G-5 and remaxol as a component of infusion therapy have promoted a bile outflow intensity enhancement in early postoperative period in comparison with such while Ringer solution and 10% solution of glucose application. Remaxol more effectively have eliminated a hyperbilirubinemia, enzymemia and a HFBO disorder, than sterofundin-G-5.